Comparison of Latanoprost and Brimonidine in the treatment of open angle glaucoma
10.3980/j.issn.1672-5123.2015.7.40
- VernacularTitle:拉坦前列腺素与溴莫尼定治疗开角型青光眼的疗效对比
- Author:
Man, LUO
;
Cha-Ying, MIAO
;
Wei, CHEN
;
Hai-Ying, LI
;
Da-Liang, WANG
;
Ping, LIU
- Publication Type:Journal Article
- Keywords:
latanoprost;
brimonidine;
open angle glaucoma;
intraocular pressure
- From:
International Eye Science
2015;(7):1256-1258
- CountryChina
- Language:Chinese
-
Abstract:
AlM:To compare the efficacy and safety of latanoprost and brimonidine in the treatment of open angle glaucoma, and provide reference for rational drug use.METHODS:A total of 121 cases ( 136 eyes ) who were diagnosed as primary open angle glaucoma were selected in this study, and they were randomly divided into experimental group (62 cases, 70 eyes) and control group ( 59 cases, 66 eyes) according to different drug treatment. Patients in the control group received brimonidine eye drops twice a day, while patients in the experimental group received latanoprost eye drops once a day. The intraocular pressure, visual acuity and adverse reactions were checked of the two groups in the following 3mo.RESULTS:The intraocular pressure of patients in the control group was 18. 1 ± 1. 3mmHg, while the experimental group was 17. 0 ± 0. 9mmHg after 12wk of treatment, which were both lower than before (P<0. 05). The fluctuation of intraocular pressure in the experimental group was significantly lower than that of the control group. There was no significant difference in the LogMAR visual acuity between before and after treatment in the control group, while the LogMAR visual acuity of the experimental group was significantly improved. The control group had hyperemia, burning sensation, tearing, eyelid edema and other adverse side effects, and the experimental group had little adverse reactions. CONCLUSlON: Latanoprost can significantly reduce intraocular pressure in glaucoma patients with in the follow- up time, and reduce the impact of elevated intraocular pressure in the vision of glaucoma patients, with little adverse reaction, worthy of clinical application.
